Pratik Multani
About Pratik Multani
Pratik Multani, MD, serves as the Chief Medical Officer with a distinguished background in medical academia and biotechnology, including significant roles at Harvard Medical School, Massachusetts General Hospital, and several biotech firms.
Pratik Multani's Professional Background
Pratik Multani serves as the Chief Medical Officer (CMO) with significant experience in both academic and clinical settings. His professional journey involves leadership roles at notable biotech companies, including Ignyta, Fate Therapeutics, Kalypsys, Kanisa, and Salmedix. Multani started his biotech career at Biogen Idec, contributing to the development of Zevalin and Rituxan for non-Hodgkin lymphoma.
Pratik Multani's Academic and Clinical Experience
Pratik Multani has a robust academic and clinical background, having held positions at Harvard Medical School and Massachusetts General Hospital. His academic trajectory includes completing a fellowship in hematology and oncology at Dana-Farber/Partners and an internship and residency in internal medicine at Massachusetts General Hospital. He holds an MD from Harvard Medical School and an MS in clinical epidemiology from Harvard School of Public Health.
Leadership at Ignyta
As the Chief Medical Officer at Ignyta, Pratik Multani led development and regulatory activities for multiple clinical stage assets, including entrectinib. His leadership at Ignyta focused on bringing innovative therapies through the clinical and regulatory pathways, advancing the company's mission to develop precision medicines targeting cancers.
Board Memberships: Erasca and Chimerix
Pratik Multani serves on the board of directors of Erasca and Chimerix (NASDAQ: CMRX). His role in these organizations demonstrates his commitment to guiding and shaping biotech companies that focus on developing therapies for critical diseases.
Pratik Multani's Educational Background
Pratik Multani received his MD from Harvard Medical School, a prestigious institution well-regarded for its contribution to medical education and research. Additionally, he earned an MS in clinical epidemiology from the Harvard School of Public Health, reflecting his dedication to integrating clinical research and epidemiological principles in his medical practice.